- Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia
- Acquired Hypofibrinogenemia
- Bleeding Treatment
Fibrinogen Concentrates Market size was valued at USD 2,864 million in 2023 and is poised to grow at a significant CAGR of 5.11% from 2024-2030. Due to the increase in the number of cases of bleeding disorders such as congenital afibrinogenemia, hypofibrinogenemia dysfibrinogenemia, low levels of fibrinogen could lead to thrombosis, blood clot formation, and other disorders. Fibrinogen Increasing the R&D activities in biotechnology, increasing awareness, increasing medical infrastructure, and rising government emphasis on the healthcare sector will fuel the market growth. However, the high cost of fibrinogen concentrates test, lack of skilled medical professionals and the concerns related to adverse effects such as nausea, vomiting, chills, dyspnea, and arterial thrombosis are the major factors that hinder the growth of the fibrinogen concentrates market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
In the recent years, Due to changing in the life styles and increased in the stress levels which leads to increase the number of many blood related disorders such as congenital afibrinogenemia, hypofibrogenemia, dysfibrinogenemia and others. Mainly, fibrinogen concentrates are utilized for the preparation of anti coagulates which is used to treat the above disorders. In addition, increasing expenditure on healthcare, growing awareness regarding the fibrinogen concentrates and rising biologic therapy, increasing drug development and Food and Drug Administration (FDA) approvals are estimated to boost market growth in near future.
The fibrinogen concentrates market size was valued at USD 2,864 million in 2023
Hualan Biological Engineering, Jiangxi Boya Bio-Pharmaceutical, LFB Group, ProFibrix BV, Shanghai RAAS
North America is dominating the fibrinogen concentrates market
1. Executive Summary |
2. Global Fibrinogen Concentrates Market Introduction |
2.1. Global Fibrinogen Concentrates Market - Taxonomy |
2.2. Global Fibrinogen Concentrates Market - Definitions |
2.2.1. Disease Indication |
2.2.2. Distribution Channel |
2.2.3. Region |
3. Global Fibrinogen Concentrates Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Key Developments |
4. Global Fibrinogen Concentrates Market By Disease Indication, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
4.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
4.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3. Market Opportunity Analysis |
4.2. Acquired Hypofibrinogenemia |
4.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3. Market Opportunity Analysis |
4.3. Bleeding Treatment |
4.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
5. Global Fibrinogen Concentrates Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Hospitals |
5 1 1 Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Ambulatory Surgical Centers |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Fibrinogen Concentrates Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. North America |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Europe |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Asia Pacific |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Latin America |
6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. MEA |
6.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Global Fibrinogen Concentrates Market - Opportunity Analysis Index, By Distribution Channel, Disease Indication, and Region, 2024-2030 |
7. North America Fibrinogen Concentrates Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Disease Indication Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
7.1.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
7.1.2. Acquired Hypofibrinogenemia |
7.1.3. Bleeding Treatment |
7.2. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
7.2.1. Hospitals |
7.2.2. Ambulatory Surgical Centers |
7.2.3. Others |
7.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
7.3.1. USA |
7.3.2. Canada |
8. Europe Fibrinogen Concentrates Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. Disease Indication Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
8.1.2. Acquired Hypofibrinogenemia |
8.1.3. Bleeding Treatment |
8.2. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Hospitals |
8.2.2. Ambulatory Surgical Centers |
8.2.3. Others |
8.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1. Germany |
8.3.2. UK |
8.3.3. France |
8.3.4. Italy |
8.3.5. Spain |
8.3.6. Rest of Europe |
9. Asia Pacific Fibrinogen Concentrates Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Disease Indication Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
9.1.2. Acquired Hypofibrinogenemia |
9.1.3. Bleeding Treatment |
9.2. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Hospitals |
9.2.2. Ambulatory Surgical Centers |
9.2.3. Others |
9.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1. China |
9.3.2. India |
9.3.3. Japan |
9.3.4. South Korea |
9.3.5. ASEAN Countries |
9.3.6. Rest of APAC |
10. Latin America Fibrinogen Concentrates Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Disease Indication Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
10.1.2. Acquired Hypofibrinogenemia |
10.1.3. Bleeding Treatment |
10.2. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Hospitals |
10.2.2. Ambulatory Surgical Centers |
10.2.3. Others |
10.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Brazil |
10.3.2. Mexico |
10.3.3. Argentina |
10.3.4. Rest of Latin America |
11. MEA Fibrinogen Concentrates Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Disease Indication Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia |
11.1.2. Acquired Hypofibrinogenemia |
11.1.3. Bleeding Treatment |
11.2. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Hospitals |
11.2.2. Ambulatory Surgical Centers |
11.2.3. Others |
11.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. GCC Countries |
11.3.2. Israel |
11.3.3. South Africa |
11.3.4. Rest of MEA |
12. Competition Landscape |
12.1. Strategic Dashboard of Top Market Players |
12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
12.2.1. CSL Behring |
12.2.2. Baxter International Inc |
12.2.3. GC Biopharma corp |
12.2.4. LFB Group |
12.2.5. Shanghai RAAS |
12.2.6. Octapharma AG |
12.2.7. Novartis AG |
12.2.8. Harbin Pacific Biopharmaceutical Co. Ltd |
12.2.9. Biotest AG |
12.2.10. Japan Blood Products Organization |
13. Research Methodology |
14. Key Assumptions and Acronyms |